株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

パラインフルエンザウイルス感染症 - 市場洞察、疫学、市場予測 2028年

Parainfluenza Virus Infection- Market Insights, Epidemiology and Market Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 888158
出版日 ページ情報 英文 127 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
パラインフルエンザウイルス感染症 - 市場洞察、疫学、市場予測 2028年 Parainfluenza Virus Infection- Market Insights, Epidemiology and Market Forecast-2028
出版日: 2019年07月01日 ページ情報: 英文 127 Pages
概要

当レポートでは、主要8カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本、中国)のパラインフルエンザウイルス感染症市場を調査し、疾病の概要や現行の治療法、新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 主な洞察

第2章 市場の概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 病気背景と概要:パラインフルエンザウイルス感染症

  • イントロダクション
  • 血清型
  • 一般症状
  • 分子生物学
  • 病因と免疫学
  • 臨床症状
  • 診断
  • 診断ガイドライン
  • 治療と予防

第4章 疫学と患者人口:主な調査結果

  • 主要8カ国の総有病数
  • 主要8カ国の総診患者数

第5章 パラインフルエンザウイルス感染症の疫学:国別

  • 造血幹細胞(HSCT)の登録と研究
  • 米国
    • 仮定と理論的根拠
    • 有病数
    • 診断患者数
    • 有病数:血清型別
    • 造血幹細胞移植(HSCT)患者における有病数
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本
  • 中国

第6章 アンメットニーズ

第7章 新薬

  • キークロスコンペティション
  • DAS181:Ansun Biopharma
    • 医薬品概要
    • その他の開発活動
    • 臨床開発
    • 製品プロファイル

第8章 パラインフルエンザウイルス感染症:主要8カ国の分析

  • 主な調査結果
  • 主要8カ国の市場規模

第9章 米国のパラインフルエンザウイルス感染症市場

  • 総市場規模
  • 市場規模:治療薬別

第10章 EU5カ国のパラインフルエンザウイルス感染症市場

  • ドイツ
    • 総市場規模
    • 市場規模:治療薬別
  • フランス
  • イタリア
  • スペイン
  • 英国

第11章 日本のパラインフルエンザウイルス感染症市場

  • 総市場規模
  • 市場規模:治療薬別

第12章 中国のパラインフルエンザウイルス感染症市場

  • 総市場規模
  • 市場規模:治療薬別

第13章 市場の成長要因

第14章 市場の障壁

第15章 付録

  • 調査手法

第16章 DelveInsightのサービス内容

第17章 免責事項

第18章 DelveInsightについて

図表

List of Tables

  • Table 1 Taxonomic classification of HPIV subtypes 1-4 within the Paramyxoviridae family
  • Table 2 Characterization of HPIV common structural proteins
  • Table 3 Total Population of Parainfluenza Virus Infection in the G8 (2017-2028)
  • Table 4 Total Diagnosed Population of Parainfluenza Virus Infection in the G8 Countries (2017-2028)
  • Table 5 Parainfluenza Virus Infection Prevalent Population in the United States (2017-2028)
  • Table 6 Parainfluenza Virus Infection Diagnosed Prevalent Population in the United States (2017-2028)
  • Table 7 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United States (2017-2028)
  • Table 8 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United States (2017-2028)
  • Table 9 Parainfluenza Virus Infection Prevalent Population in Germany (2017-2028)
  • Table10 Parainfluenza Virus Infection Diagnosed Prevalent Population in Germany (2017-2028)
  • Table11 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Germany (2017-2028)
  • Table12 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Germany (2017-2028)
  • Table13 Parainfluenza Virus Infection Prevalent Population in France (2017-2028)
  • Table14 Parainfluenza Virus Infection Diagnosed Prevalent Population in France (2017-2028)
  • Table15 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in France (2017-2028)
  • Table16 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in France (2017-2028)
  • Table17 Parainfluenza Virus Infection Prevalent Population in Italy (2017-2028)
  • Table18 Parainfluenza Virus Infection Diagnosed Prevalent Population in Italy (2017-2028)
  • Table19 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Italy (2017-2028)
  • Table20 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Italy (2017-2028)
  • Table21 Parainfluenza Virus Infection Prevalent Population in Spain (2017-2028)
  • Table22 Parainfluenza Virus Infection Diagnosed Prevalent Population in Spain (2017-2028)
  • Table23 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Spain (2017-2028)
  • Table24 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Spain (2017-2028)
  • Table25 Parainfluenza Virus Infection Prevalent Population in the United Kingdom (2017-2028)
  • Table26 Parainfluenza Virus Infection Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Table27 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United Kingdom (2017-2028)
  • Table28 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United Kingdom (2017-2028)
  • Table29 Parainfluenza Virus Infection Prevalent Population in Japan (2017-2028)
  • Table30 Parainfluenza Virus Infection Diagnosed Prevalent Population in Japan (2017-2028)
  • Table31 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Japan (2017-2028)
  • Table32 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Japan (2017-2028)
  • Table33 Parainfluenza Virus Infection Prevalent Population in China (2017-2028)
  • Table34 Parainfluenza Virus Infection Diagnosed Prevalent Population in China (2017-2028)
  • Table35 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in China (2017-2028)
  • Table36 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in China (2017-2028)
  • Table37 Comparison of emerging drugs under development
  • Table38 Clinical Trial Description
  • Table39 G8 Countries Market Size of Parainfluenza Virus Infection in USD Million (2017-2028)
  • Table40 United States Market Size of Parainfluenza Virus Infection, USD Million (2017-2028)
  • Table41 Market size of Parainfluenza Virus Infection by therapies in the United States, in USD Million (2017-2028)
  • Table42 Market Size of Parainfluenza Virus Infection in Germany, in USD Million (2017-2028)
  • Table43 Market size of Parainfluenza Virus Infection by therapies in Germany, in USD Million (2017-2028)
  • Table44 Market Size of Parainfluenza Virus Infection in France, in USD Million (2017-2028)
  • Table45 Market size of Parainfluenza Virus Infection by therapies in France, in USD Million (2017-2028)
  • Table46 Market Size of Parainfluenza Virus Infection in Italy, in USD Million (2017-2028)
  • Table47 Market size of Parainfluenza Virus Infection by therapies in Italy, in USD Million (2017-2028)
  • Table48 Market Size of Parainfluenza Virus Infection in Spain, in USD Million (2017-2028)
  • Table49 Market size of Parainfluenza Virus Infection by therapies in Spain, in USD Million (2017-2028)
  • Table50 Market Size of Parainfluenza Virus Infection in the UK, in USD Million (2017-2028)
  • Table51 Market size of Parainfluenza Virus Infection by therapies in the United Kingdom, in USD Million (2017-2028)
  • Table52 Market Size of Parainfluenza Virus Infection in Japan, in USD Million (2017-2028)
  • Table53 Market size of Parainfluenza Virus Infection by therapies in Japan, in USD Million (2017-2028)
  • Table54 Market Size of Parainfluenza Virus Infection in China, in USD Million (2017-2028)
  • Table55 Market size of Parainfluenza Virus Infection by therapies in China, in USD Million (2017-2028)

List of Figures

  • Figure 1 Symptoms of Parainfluenza Virus Infection
  • Figure 2 Structure of Human Parainfluenza Virus serotypes 1 to 4
  • Figure 3 Cycle of attachment, fusion, and replication for Parainfluenza Viruses
  • Figure 4 Pathogenesis and disease progression of HPIV associated Croup
  • Figure 5 Total Patient Population of Parainfluenza Virus Infection in the G8 (2017-2028)
  • Figure 6 Total Diagnosed Patient Population of Parainfluenza Virus Infection in the G8 (2017-2028)
  • Figure 7 Parainfluenza Virus Infection Prevalent Population in the United States (2017-2028)
  • Figure 8 Parainfluenza Virus Infection Diagnosed Prevalent Population in the United States (2017-2028)
  • Figure 9 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United States (2017-2028)
  • Figure 10 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United States (2017-2028)
  • Figure 11 Parainfluenza Virus Infection Prevalent Population in Germany (2017-2028)
  • Figure 12 Parainfluenza Virus Infection Diagnosed Prevalent Population in Germany (2017-2028)
  • Figure 13 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Germany (2017-2028)
  • Figure 14 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Germany (2017-2028)
  • Figure 15 Parainfluenza Virus Infection Prevalent Population in France (2017-2028)
  • Figure 16 Parainfluenza Virus Infection Diagnosed Prevalent Population in France (2017-2028)
  • Figure 17 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in France (2017-2028)
  • Figure 18 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in France (2017-2028)
  • Figure 19 Parainfluenza Virus Infection Prevalent Population in Italy (2017-2028)
  • Figure 20 Parainfluenza Virus Infection Diagnosed Prevalent Population in Italy (2017-2028)
  • Figure 21 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Italy (2017-2028)
  • Figure 22 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Italy (2017-2028)
  • Figure 23 Parainfluenza Virus Infection Prevalent Population in Spain (2017-2028)
  • Figure 24 Parainfluenza Virus Infection Diagnosed Prevalent Population in Spain (2017-2028)
  • Figure 25 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Spain (2017-2028)
  • Figure 26 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Spain (2017-2028)
  • Figure 27 Parainfluenza Virus Infection Prevalent Population in the United Kingdom (2017-2028)
  • Figure 28 Parainfluenza Virus Infection Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Figure 29 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United Kingdom (2017-2028)
  • Figure 30 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United Kingdom (2017-2028)
  • Figure 31 Parainfluenza Virus Infection Prevalent Population in Japan (2017-2028)
  • Figure 32 Parainfluenza Virus Infection Diagnosed Prevalent Population in Japan (2017-2028)
  • Figure 33 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Japan (2017-2028)
  • Figure 34 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Japan (2017-2028)
  • Figure 35 Parainfluenza Virus Infection Prevalent Population in China (2017-2028)
  • Figure 36 Parainfluenza Virus Infection Diagnosed Prevalent Population in China (2017-2028)
  • Figure 37 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in China (2017-2028)
  • Figure 38 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in China (2017-2028)
  • Figure 39 Unmet Needs of Parainfluenza Virus Infection
  • Figure 40 G8 Counties Market Size of Parainfluenza Virus Infection in USD Million (2017-2028)
  • Figure 41 Market Size of Parainfluenza Virus Infection in the United States, USD Millions (2017-2028)
  • Figure 42 Market size of Parainfluenza Virus Infection by therapies in the US, in USD Million (2017-2028)
  • Figure 43 Market Size of Parainfluenza Virus Infection in Germany, USD Million (2017-2028)
  • Figure 44 Market Size of Parainfluenza Virus Infection by therapies, in Germany, in USD Million (2017-2028)
  • Figure 45 Market Size of Parainfluenza Virus Infection in France, USD Million (2017-2028)
  • Figure 46 Market Size of Parainfluenza Virus Infection by therapies, in France, in USD Million (2017-2028)
  • Figure 47 Market Size of Parainfluenza Virus Infection in Italy, USD Million (2017-2028)
  • Figure 48 Market Size of Parainfluenza Virus Infection by therapies in Italy, in USD Million (2017-2028)
  • Figure 49 Market Size of Parainfluenza Virus Infection in Spain, USD Million (2017-2028)
  • Figure 50 Market Size of Parainfluenza Virus Infection by therapies in Spain, in USD Million (2017-2028)
  • Figure 51 Market Size of Parainfluenza Virus Infection in the UK, USD Million (2017-2028)
  • Figure 52 Market Size of Parainfluenza Virus Infection by therapies in the UK, in USD Million (2017-2028)
  • Figure 53 Market Size of Parainfluenza Virus Infection in Japan, USD Million (2017-2028)
  • Figure 54 Market Size of Parainfluenza Virus Infection by therapies in Japan, in USD Million (2017-2028)
  • Figure 55 Market Size of Parainfluenza Virus Infection in China, USD Million (2017-2028)
  • Figure 56 Market Size of Parainfluenza Virus Infection by therapies in China, in USD Million (2017-2028)
  • Figure 57 Market Drivers
  • Figure 58 Market Barriers
目次
Product Code: DIMI0645

DelveInsight's 'Parainfluenza Virus Infection- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Parainfluenza Virus Infection in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Parainfluenza Virus Infection from 2017 to 2028 segmented by G8 countries. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • China

Study Period: 2017-2028

Parainfluenza Virus Infection - Disease Understanding and Treatment Algorithm

The Parainfluenza Viruses (PIVs) are non-segmented, negative-strand RNA viruses of the family Paramyxoviridae. The paramyxoviruses include not only the PIVs but also several other important human pathogens transmitted through the respiratory route such as a human respiratory syncytial virus (HRSV), metapneumovirus, measles virus, and mumps virus. The human PIVs (HPIVs) consist of four serotypes (HPIV1-4), are a common cause of upper respiratory tract (URT) infections and are a leading cause of lower respiratory tract (LRT) disease in infants and children. The HPIVs are efficiently transmitted by direct contact and exposure to nasopharyngeal secretions, and nearly all children are infected with HPIV3 by age 2 and with HPIV1 and HPIV2 by age 5. Anti-PIV vaccines or drugs are not available, and therefore, non-pharmaceutical interventions are currently the only means of control. The treatment of the Parainfluenza Virus Infection is only supportive and symptomatic. Hence, no drug is approved for the treatment of the disease, therefore, it is considered as the major issue of the disease.

The DelveInsight Parainfluenza Virus Infection market report gives the thorough understanding of the Parainfluenza Virus Infection by including details such as disease introduction, serotypes, signs and symptoms, molecular biology, pathogenesis and immunology, clinical manifestations, diagnosis and treatment.

Parainfluenza Virus Infection Epidemiology

Over the last decade, it has been found that there has been a considerable change in both the nomenclature and taxonomic relationships of human parainfluenza viruses (HPIV). HPIVs were first discovered in the late 1950s when three different viruses were recovered from children with a lower respiratory disease which proved to be unique and easily separated from the myxoviruses (influenza virus) which closely resemble the parainfluenza virus. Parainfluenza virus (PIV) is the second leading cause of hospitalization for respiratory illness in young children in the United States. Infection can result in a full range of respiratory illness, including bronchiolitis, croup, and pneumonia.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Parainfluenza Virus Infection in the G8 countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2017-2028 for the following aspects:

  • Prevalent Population of Parainfluenza Virus Infection
  • Diagnosed Prevalent Population of Parainfluenza Virus Infection
  • Prevalent Population of Parainfluenza Virus Infection based on the Serotypes
  • Prevalent Population of Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients

According to a study conducted by H. Kelly et al. titled "Parainfluenza Viruses" the study threw light on the number of cases that come into the picture due to parainfluenza virus infections. It was found that between 500,000 and 800,000 LRI hospitalizations (in persons younger than 18 years) in the United States each year. Looking at the aspect of admitted cases for PIV according to serotype epidemiology each HPIV-1 resulted in an estimated 18,000- 3,50,000 US children younger than 5 years. For HPIV-2 as many as around 6000 children younger than 18 years may be hospitalized each year in the United States. About 60% of all HPIV-2 infections occur in children younger than 5 years, and although the peak incidence is between 1 and 2 years of age. For HPIV-3 scenario which is the most common amongst other serotypes, it was found that young infants (younger than 6 months) are particularly vulnerable to infection. Unlike the other HPIV, approximately 40% of HPIV-3 infections are in the first year of life. Bronchiolitis and pneumonia are the most common clinical presentations with HPIV-3. It is also worth noting that approximately 18,000 infants and children are hospitalized each year in the United States because of LRI caused by HPIV-3.

An another study conducted by J. Jerome et al. titled "Epidemiological, Molecular, and Clinical Features of Enterovirus Respiratory Infections in French Children between 1999 and 2005" concluded the Positive respiratory viral findings in the nasopharyngeal samples of 11,509 consecutive children attending one of the five referent pediatric emergency departments of the region Champagne Ardenne (France) from 1999 to 2005. Out of 11,509 children, 2444 (21%) were detected as positive for respiratory viral infections. The frequency of PIV Type-3 was found to be 2.4% amongst all positive respiratory viral infections.

Parainfluenza Virus Infection Drug Chapters

This segment of the Parainfluenza Virus Infection report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Parainfluenza Virus Infection, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Parainfluenza Virus Infection & awareness of the disease. The overall dynamics of Parainfluenza Virus Infection market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Ansun Biopharma will significantly increase the market during the forecast period (2019-2028).

Parainfluenza Virus Infection Market Outlook

The Parainfluenza Virus Infection market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

The treatment landscape of Human Parainfluenza Virus (HPIV) comprises of very few pharmacotherapies. Currently, there are no antiviral agents with proven efficacy for Parainfluenza Virus Infection available in the market. The treatment and management of HPIV infection in healthy children and adults is mostly symptomatic. Parainfluenza Virus Infection is a common cause of significant mortality and morbidity in lung transplant recipients as well as in hematopoietic cell transplant recipients. The usual treatment and management for Human Parainfluenza Virus (HPIV) are focused on Symptomatic treatment, including preventive strategies. The current approaches to HPIV vaccines include intranasal administration of live attenuated strains, subunit strategies using the HN and F proteins, recombinant bovine/human viruses, and strains engineered using reverse genetics. In the United States, mortality is unusual and the cost of these viruses is seen mostly in health care utilization, hospitalization, lost productivity for parents, and, perhaps, long-term respiratory tract sequel in children. Ribavirin is Pharmacological drug used for the treatment of PIV infections, which has shown promising results in animal models and children with severe combined immunodeficiency. Ribavirin is a synthetic nucleoside analog which has broad-spectrum in vitro and in vivo activity against many RNA and DNA viruses. Corticosteroids are used as the primary treatment for croup and are known to be beneficial for mild-, moderate-to-severe croup. Corticosteroids are administered orally or given intramuscularly in the form of dexamethasone or prednisolone and both have been shown to be superior to inhaled therapy with budesonide. The drugs such as acetaminophen, ibuprofen are used commonly for the treatment of symptoms associated with PIV infection such as pain and fever. Other than these several other symptomatic relief options are also available like Heliox, nebulized epinephrine, etc.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Parainfluenza Virus Infection in G8 is expected to change from 2019-2028.

Parainfluenza Virus Infection Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Parainfluenza Virus Infection such as DAS-181 (Ansun Biopharma) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Parainfluenza Virus Infection market.

Parainfluenza Virus Infection Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Parainfluenza Virus Infection Report Key Strengths

  • 10 Year Forecast
  • G8 Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Parainfluenza Virus Infection Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Parainfluenza Virus Infection market
  • Organize sales and marketing efforts by identifying the best opportunities for Parainfluenza Virus Infection market
  • To understand the future market competition in the Parainfluenza Virus Infection market.

Table of Contents

1. Key Insights

2. Parainfluenza Virus Infection Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Parainfluenza Virus Infection in 2017
  • 2.2. Market Share (%) Distribution of Parainfluenza Virus Infection in 2028

3. Disease Background and Overview: Parainfluenza Virus Infection

  • 3.1. Introduction
  • 3.2. Serotypes
  • 3.3. Common Symptoms
  • 3.4. Molecular Biology
  • 3.5. Pathogenesis and Immunology
  • 3.6. Clinical Manifestations
  • 3.7. Diagnosis
  • 3.8. Diagnostic Guidelines
  • 3.9. Treatment and prevention

4. Epidemiology and Patient Population: Key Findings

  • 4.1. G8 Total Patient Population of Parainfluenza Virus Infection
  • 4.2. G8 Total Diagnosed Patient Population of Parainfluenza Virus Infection

5. Country Wise-Epidemiology of Parainfluenza Virus Infection

  • 5.1. Registries and Studies for HSCT
  • 5.2. United States
    • 5.2.1. Assumptions and Rationale
    • 5.2.2. Parainfluenza Virus Infection Prevalent Population in the United States
    • 5.2.3. Parainfluenza Virus Infection Diagnosed Prevalent Population in the United States
    • 5.2.4. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United States
    • 5.2.5. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United States
  • 5.3. EU5 Countries
    • 5.3.1. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Parainfluenza Virus Infection Prevalent Population in Germany
    • 5.4.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in Germany
    • 5.4.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Germany
    • 5.4.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Germany
  • 5.5. France
    • 5.5.1. Parainfluenza Virus Infection Prevalent Population in France
    • 5.5.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in France
    • 5.5.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in France
    • 5.5.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in France
  • 5.6. Italy
    • 5.6.1. Parainfluenza Virus Infection Prevalent Population in Italy
    • 5.6.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in Italy
    • 5.6.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Italy
    • 5.6.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Italy
  • 5.7. Spain
    • 5.7.1. Parainfluenza Virus Infection Prevalent Population in Spain
    • 5.7.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in Spain
    • 5.7.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Spain
    • 5.7.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Spain
  • 5.8. United Kingdom
    • 5.8.1. Parainfluenza Virus Infection Prevalent Population in the United Kingdom
    • 5.8.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in the United Kingdom
    • 5.8.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United Kingdom
    • 5.8.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United Kingdom
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Parainfluenza Virus Infection Prevalent Population in Japan
    • 5.9.3. Parainfluenza Virus Infection Diagnosed Prevalent Population in Japan
    • 5.9.4. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Japan
    • 5.9.5. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Japan
  • 5.10. China
    • 5.10.1. Assumptions and Rationale
    • 5.10.2. Parainfluenza Virus Infection Prevalent Population in China
    • 5.10.3. Parainfluenza Virus Infection Diagnosed Prevalent Population in China
    • 5.10.4. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in China
    • 5.10.5. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in China

6. Unmet Needs

7. Emerging Drugs

  • 7.1. Key Cross Competition
  • 7.2. DAS181: Ansun Biopharma
    • 7.2.1. Product Description
    • 7.2.2. Other Development Activities
    • 7.2.3. Clinical Development
    • 7.2.4. Product Profile

8. Parainfluenza Virus Infection: G8 Countries Analysis

  • 8.1. Key Findings
  • 8.2. Market Size of Parainfluenza Virus Infection in the G8 countries

9. The United States Market Outlook

  • 9.1. United States Market Size
    • 9.1.1. Total Market size of Parainfluenza Virus Infection
    • 9.1.2. Market Size by Therapies

10. EU-5 Countries: Market Outlook

    • 10.1.1. Total Market size of Parainfluenza Virus Infection in Germany
    • 10.1.2. Market Size by Therapies
  • 10.2. France
    • 10.2.1. Total Market Size of Parainfluenza Virus Infection
    • 10.2.2. Market Size by Therapies
  • 10.3. Italy
    • 10.3.1. Total Market Size of Parainfluenza Virus Infection
    • 10.3.2. Market Size by Therapies
  • 10.4. Spain
    • 10.4.1. Total Market Size of Parainfluenza Virus Infection
    • 10.4.2. Market Size by Therapies
  • 10.5. United Kingdom
    • 10.5.1. Total Market Size of Parainfluenza Virus Infection
    • 10.5.2. Market Size by Therapies

11. Japan: Market Outlook

  • 11.1. Japan market Size
    • 11.1.1. Total Market Size of Parainfluenza Virus Infection
    • 11.1.2. Market Size by Therapies

12. China: Market Outlook

  • 12.1. China Market Size
    • 12.1.1. Total Market Size of Parainfluenza Virus Infection
    • 12.1.2. Market Size by Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

  • 15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

Back to Top